PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States Food and Drug Administration Post published:December 7, 2021 Post category:Press Release
PsyBio Therapeutics Furthers Intellectual Property Portfolio with Six New Manufacturing Patent Applications Post published:November 19, 2021 Post category:Press Release
PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs Post published:August 16, 2021 Post category:Press Release
PsyBio Therapeutics Adds NMDA Receptor Antagonists and Associated Analogues into its Intellectual Property Portfolio Post published:August 4, 2021 Post category:Press Release
PsyBio Therapeutics Augments Intellectual Property Portfolio with Filing of Next Novel Psychedelic Compositions and Methods of Treatment Patent Post published:July 13, 2021 Post category:Press Release
PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie Post published:June 22, 2021 Post category:Press Release
PsyBio and Miami University Broaden Partnership Agreement for the Continued Advancement of its Neuropsychiatric Drug Discovery Platform, Expediting its IND Submission to the FDA Post published:April 26, 2021 Post category:Press Release
PsyBio Therapeutics Announces Application to List on OTCQX Post published:April 13, 2021 Post category:Press Release
PsyBio Therapeutics Announces Retention of Market Maker Post published:March 4, 2021 Post category:Press Release
PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization Post published:March 2, 2021 Post category:Press Release